MK-677

MK-677 is a non-peptide oral growth hormone secretagogue developed by Merck. Unlike peptide-based GH secretagogues that require injection, MK-677 is taken orally, making it significantly more convenient for research and personal use. It functions as a ghrelin receptor agonist, mimicking the effects of the naturally produced hormone ghrelin, which stimulates growth hormone release from the anterior pituitary.

Originally developed in the 1990s, MK-677 has been extensively studied in clinical trials for potential therapeutic applications in growth hormone deficiency, muscle wasting, and age-related decline. Unlike traditional GH replacement therapy, MK-677 does not directly inject growth hormone but instead stimulates the body's own GH production, maintaining the natural pulsatile secretion pattern that makes endogenous GH more physiological than exogenous hormone therapy.

The compound is particularly notable because it increases GH and IGF-1 production without suppressing gonadotropin or increasing cortisol, distinguishing it from some other peptides and making it theoretically more compatible with long-term use protocols.

Ghrelin receptor activation: MK-677 binds to and activates ghrelin receptors (GHS-R1a) in the hypothalamus and pituitary gland. This activation stimulates the release of growth hormone-releasing hormone (GHRH) and inhibits somatostatin, leading to increased GH secretion.

GH pulse amplification: Research shows MK-677 increases both the amplitude and frequency of GH pulses, creating a more robust and sustained elevation in circulating growth hormone levels throughout the day and night.

IGF-1 elevation: Through elevated GH levels, MK-677 indirectly increases circulating IGF-1 and tissue-local IGF-1 production. IGF-1 is responsible for many of the anabolic effects associated with growth hormone, including muscle protein synthesis, bone growth, and cellular proliferation.

Preserved natural physiology: Unlike exogenous GH injection, MK-677 maintains the natural pulsatile GH secretion pattern and does not suppress the body's endogenous GH production, making it more physiologically sound for extended protocols.

MK-677 has been studied in multiple clinical trials, primarily focusing on GH-deficient populations and age-related decline:

GH elevation: Clinical studies consistently demonstrate 1.5-3x increases in basal GH levels, with some evidence of sustained elevation throughout 24-hour periods. A 12-week study showed GH increased from baseline ~0.3 mcg/mL to 2.0+ mcg/mL in treated groups.

Muscle mass and strength: A study in GH-deficient adults showed significant improvements in lean body mass and muscle strength after 12 weeks of MK-677 administration (Bach et al., 2005).

Bone density: Research indicates MK-677 may improve markers of bone turnover and potentially increase bone mineral density, relevant for osteoporosis prevention (Nass et al., 2008).

Body composition: Studies have shown decreases in fat mass alongside increases in lean mass, suggesting favorable metabolic effects beyond simple GH elevation.

Important limitation: Most published clinical trials in humans are relatively short-term (8-16 weeks). Long-term safety and efficacy data in healthy adult populations remain limited.

• Muscle growth and strength gains — IGF-1 elevation supports muscle protein synthesis and hypertrophy
• Improved body composition — increased lean mass, decreased fat mass
• Enhanced recovery — accelerated healing from training-induced muscle damage
• Bone density improvement — relevant for long-term skeletal health
• Better sleep quality — ghrelin activation may improve sleep architecture
• Increased appetite — beneficial for those struggling to eat in surplus for muscle gain
• Oral convenience — no injections required, unlike peptide GH secretagogues

Standard research dosing: MK-677 is typically administered orally at doses of 10-25 mg daily. Most research protocols use 25 mg daily, often split into two doses (12.5 mg twice daily).

Timing: Taking MK-677 before bed may optimize sleep quality and nocturnal GH secretion, though many protocols dose in the morning for convenience.

Duration: Research protocols typically run for 12-16 weeks. Some anecdotal reports suggest longer cycles (8-12 weeks on, 4 weeks off), though optimal long-term dosing schedules remain unclear.

Clinical trial dosing: Published clinical trials have used 10 mg, 25 mg, and 50 mg daily doses, with 25 mg showing optimal benefit-to-side-effect ratio in many studies.

MK-677 has generally shown a favorable safety profile in clinical trials:

Common side effects: Increased appetite (nearly universal), water retention/mild edema, mild carpal tunnel syndrome or joint aches in some users, possible elevation of fasting glucose and insulin (metabolic effects).

Less common: Mild prolactin elevation (within normal ranges in most studies), mood/sleep changes (usually improvements), temporary muscle soreness during initial protocols.

Safety profile: Clinical trials of up to 2 years have not identified major safety concerns. No significant increases in cancer risk, cardiovascular events, or serious adverse events were reported in published clinical data.

Important considerations: Individuals with untreated sleep apnea should approach MK-677 cautiously due to potential airway effects. Those at risk for or with diagnosed diabetes should monitor glucose and insulin levels. Long-term effects in healthy non-GH-deficient populations remain understudied.

MK-677 is frequently combined with other peptides and compounds:

MK-677 + Peptide secretagogues: Some protocols combine MK-677 with peptide GH secretagogues like CJC-1295 or GHRP-6 for potentially additive GH elevation, though synergy is debated in research.

MK-677 + Testosterone: Community protocols often combine MK-677 with TRT or SARMs, as elevated IGF-1 from MK-677 may enhance anabolic effects of androgens.

MK-677 + Training protocols: MK-677 is commonly used during structured resistance training programs to maximize muscle growth and recovery benefits.